Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) As of January 1, 2022, Bill Rencher, Ph.D., retired as Head of Chemistry Manufacturing Controls of Context Therapeutics Inc. (the "Company"), and transitioned into an advisory role with the Company. In his advisory role, Mr. Rencher will assist the Company with the oversight and transition of projects he previously managed. Mr. Rencher's retirement was planned and was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

In connection with his transition to an advisory role with the Company, Mr. Rencher and the Company entered into a master services agreement, which terminated Mr. Rencher's prior consulting agreement with the Company, and entered into a related statement of work (the "SOW") detailing the terms of Mr. Rencher's services that will continue through October 2022 or until the Company terminates his services to the Company. The SOW provides that Mr. Rencher will receive a retainer of $8,000 per month from January 2022 through April 2022 while performing an average of eight hours of services per week, and provides that Mr. Rencher will remain available through October 2022 to answer questions the Company may have regarding his prior services.

The foregoing is a summary description of certain terms of the master services agreement and the SOW and, by its nature, is not complete. It is qualified in its entirety by reference to the master services agreement and SOW, copies of which are attached hereto as Exhibit 99.2, and Exhibit 99.3, respectively, and are incorporated herein by reference.

Item 8.01. Other Events.

On January 5, 2022, the Company issued a press release to announce the retirement of Mr. Rencher, as well as the appointment of Christopher Beck as SVP, Operations and Mark Fletcher, Ph.D., as VP, R&D. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d)Exhibits.

Exhibit No.         Description
99.1                  Press Release issued by Context Therapeutics Inc., dated January 5, 2022
                      Master Services Agreement between Context Therapeutics Inc. and Bill
99.2#               Rencher, dated January 1, 2022
                      Statement of Work between Context Therapeutics Inc. and Bill Rencher, dated
99.3#               January 1, 2022

# Certain information has been excluded from the exhibit because it both (i) is not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses